Drugs / HMI-203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05238324 | Sep 2022 → Oct 2024 | mucopolysaccharidosis type 2 | Homology Medicines, Inc | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMI-203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05238324 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “investigational gene therapy HMI-203” NCT05238324 ↗ |
| Route | Intravenous | “HMI-203 delivered intravenously” NCT05238324 ↗ |